JP2008502738A - ヒトの癌を処置するための、ｖｅｇｆインヒビターの使用 - Google Patents

ヒトの癌を処置するための、ｖｅｇｆインヒビターの使用 Download PDF

Info

Publication number
JP2008502738A
JP2008502738A JP2007527795A JP2007527795A JP2008502738A JP 2008502738 A JP2008502738 A JP 2008502738A JP 2007527795 A JP2007527795 A JP 2007527795A JP 2007527795 A JP2007527795 A JP 2007527795A JP 2008502738 A JP2008502738 A JP 2008502738A
Authority
JP
Japan
Prior art keywords
cancer
vegf
dose
initial dose
flt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2007527795A
Other languages
English (en)
Japanese (ja)
Inventor
ジェシー エム． セダーバウム，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of JP2008502738A publication Critical patent/JP2008502738A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2007527795A 2004-06-10 2005-06-10 ヒトの癌を処置するための、ｖｅｇｆインヒビターの使用 Withdrawn JP2008502738A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57849904P 2004-06-10 2004-06-10
PCT/US2005/020762 WO2005123104A2 (en) 2004-06-10 2005-06-10 Use of vegf inhibitors for the treatment of human cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011246211A Division JP2012067116A (ja) 2004-06-10 2011-11-10 ヒトの癌を処置するための、ｖｅｇｆインヒビターの使用

Publications (1)

Publication Number Publication Date
JP2008502738A true JP2008502738A (ja) 2008-01-31

Family

ID=35510259

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007527795A Withdrawn JP2008502738A (ja) 2004-06-10 2005-06-10 ヒトの癌を処置するための、ｖｅｇｆインヒビターの使用
JP2011246211A Withdrawn JP2012067116A (ja) 2004-06-10 2011-11-10 ヒトの癌を処置するための、ｖｅｇｆインヒビターの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2011246211A Withdrawn JP2012067116A (ja) 2004-06-10 2011-11-10 ヒトの癌を処置するための、ｖｅｇｆインヒビターの使用

Country Status (9)

Country Link
US (7) US7354580B2 (enExample)
EP (2) EP2583685A1 (enExample)
JP (2) JP2008502738A (enExample)
CN (1) CN101102786A (enExample)
AU (1) AU2005254058A1 (enExample)
CA (1) CA2567686A1 (enExample)
IL (1) IL179515A0 (enExample)
MX (1) MXPA06014421A (enExample)
WO (1) WO2005123104A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013538337A (ja) * 2010-07-19 2013-10-10 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 膵臓癌の治療のためのベバシズマブ組合せ療法のための血漿バイオマーカー
US9657084B2 (en) 2014-01-25 2017-05-23 Chengdu Kanghong Biotechnologies Co., Ltd. Fusion protein inhibiting angiogenesis or growth and use thereof

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1755645A2 (en) * 2004-06-18 2007-02-28 Regeneron Pharmaceuticals, Inc. Vegf inhibitors for the treatment of malignant pleural effusion
ES2633574T3 (es) * 2005-03-25 2017-09-22 Regeneron Pharmaceuticals, Inc. Formulaciones de antagonistas de VEGF
MX2008001966A (es) * 2005-08-12 2008-03-26 Regeneron Pharma Tratamiento de enfermedades mediante administracion subcutanea de un antagonista vegf.
US8093259B2 (en) * 2006-05-25 2012-01-10 Novartis Ag 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-N-[5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)phenyl]-benzamide for treatment of melanoma
SI2944306T1 (sl) 2006-06-16 2021-04-30 Regeneron Pharmaceuticals, Inc. Formulacije antagonista VEGF, primerne za intravitrealno dajanje
GB0612721D0 (en) * 2006-06-27 2006-08-09 Novartis Ag Organic compounds
US7750124B2 (en) 2006-09-29 2010-07-06 Oncomed Pharmaceuticals, Inc. Anti-human DLL4 antibodies and compositions
ES2582656T3 (es) * 2006-12-19 2016-09-14 Genentech, Inc. Antagonistas específicos del VEGF para terapia adyuvante y neoadyuvante, y el tratamiento de tumores en fase temprana
AU2014201795B2 (en) * 2006-12-19 2016-05-19 Genentech, Inc. VEGF-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors
TWI580694B (zh) 2007-11-30 2017-05-01 建南德克公司 抗-ｖｅｇｆ抗體
KR101596539B1 (ko) * 2008-12-23 2016-02-22 제넨테크, 인크. 암 환자에서의 진단 목적용 방법 및 조성물
US9351964B2 (en) 2009-05-27 2016-05-31 Ptc Therapeutics, Inc. Methods for treating cancer and non-neoplastic conditions
EP3485908B1 (en) 2009-10-16 2021-08-18 Mereo BioPharma 5, Inc. Therapeutic combination and use of dll4 antagonist antibodies and anti-hypertensive agents
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
MX385629B (es) 2011-01-13 2025-03-18 Regeneron Pharma Uso de un antagonista de factor de crecimiento endotelial vascular para tratar trastornos oculares angiogenicos.
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
EP2546268A1 (en) 2011-07-13 2013-01-16 F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. Internalising immunoglobulin
HRP20190044T1 (hr) 2011-09-23 2019-02-22 Oncomed Pharmaceuticals, Inc. Agensi koji vežu vegf/dll4 i njihove uporabe
AU2013337811A1 (en) 2012-10-31 2015-05-14 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a DLL4 antagonist
US9745558B2 (en) 2013-02-18 2017-08-29 Vegenics Pty Limited VEGFR-3 ligand binding molecules and uses thereof
CN104004058B (zh) * 2014-06-23 2016-06-08 栾晓鹏 有关白介素-33抑制剂多肽及其应用
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
SI3170005T1 (sl) 2014-07-18 2019-08-30 Sanofi Postopek napovedovanja izida zdravljenja z afliberceptom, pacienta, pri katerem obstaja sum, da je zbolel za rakom
MX382902B (es) 2014-10-31 2025-03-13 Oncomed Pharm Inc Inhibidor de la vía noth en combinación con un agente inmunoterapéutico para usarse en el tratamiento de cáncer.
KR20170082537A (ko) * 2014-11-14 2017-07-14 제넨테크, 인크. Vegf 길항제에 대한 반응 예측
WO2017053705A1 (en) 2015-09-23 2017-03-30 Oncomed Pharmaceuticals, Inc. Methods and compositions for treatment of cancer
WO2017117464A1 (en) 2015-12-30 2017-07-06 Kodiak Sciences Inc. Antibodies and conjugates thereof
CN108496084B (zh) * 2016-01-25 2021-11-05 赛诺菲 通过测量血浆生物标记的水平预测疑似患有癌症的患者使用阿柏西普的治疗的结果的方法
WO2017143070A1 (en) * 2016-02-18 2017-08-24 University Of Massachusetts Combination therapy
KR101685532B1 (ko) * 2016-04-26 2016-12-13 한국프라임제약주식회사 혈관내피성장인자 수용체 융합단백질
ES2904939T3 (es) * 2017-03-30 2022-04-06 Progastrine Et Cancers S A R L Composiciones y métodos para detectar y tratar el cáncer de próstata utilizando una molécula de unión a progastrina
KR20200035292A (ko) * 2017-08-01 2020-04-02 피티씨 테라퓨틱스, 인크. 혈액 암 치료에 사용하기 위한 dhodh 억제제
KR102147721B1 (ko) * 2017-10-24 2020-08-25 (주)엠디바이오랩 스트렙토니그린 및 라파마이신을 유효성분으로 포함하는, 암 예방 또는 치료용 약학적 조성물
HUE059827T2 (hu) 2017-11-30 2023-01-28 Regeneron Pharma VEGF-antagonista alkalmazása angiogén szembetegségek kezelésére
US11524053B2 (en) 2018-01-26 2022-12-13 The Regents Of The University Of California Methods and compositions for treatment of angiogenic disorders using anti-VEGF agents
BR112020017872A2 (pt) 2018-03-02 2020-12-22 Kodiak Sciences Inc. Anticorpos de il-6 e construtos de fusão e conjugados dos mesmos
WO2020106049A1 (ko) * 2018-11-20 2020-05-28 (주)엠디바이오랩 스트렙토니그린 및 항암제를 모두 포함하는 암 예방 또는 치료에 사용하기 위한 약학적 조성
KR20200094110A (ko) * 2019-01-29 2020-08-06 (주)엠디바이오랩 스트렙토니그린 및 항암제를 포함하는 뇌종양 예방 또는 치료용 조성물
WO2020159171A2 (ko) * 2019-02-01 2020-08-06 (주)엠디바이오랩 스트렙토니그린 및 항암제를 포함하는 대장암 예방 또는 치료용 약학적 조성물
WO2021072265A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
IL293131A (en) 2019-11-25 2022-07-01 Univ California Long-acting vegf inhibitors for intraocular neovascularization
CN115803009A (zh) 2020-05-08 2023-03-14 瑞泽恩制药公司 用于治疗眼病和癌症的vegf阱和微阱及方法
US20220196166A1 (en) * 2020-12-18 2022-06-23 Nibco Inc. L-ball union drain valve
US11898643B1 (en) 2022-12-28 2024-02-13 Nibco Inc. Dual union ball drain valve with T-flow adjustability
US12140236B2 (en) 2023-02-08 2024-11-12 Nibco Inc. Dual union drain valve with reversible check inserts

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000075319A1 (en) * 1999-06-08 2000-12-14 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6100071A (en) * 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US7264801B2 (en) * 1998-08-11 2007-09-04 Genentech, Inc. EG-VEGF nucleic acids and polypeptides and method of use
US7087411B2 (en) * 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US6833349B2 (en) * 1999-06-08 2004-12-21 Regeneron Pharmaceuticals, Inc. Methods of treating inflammatory skin diseases
EP1626989A2 (en) * 2003-05-28 2006-02-22 Regeneron Pharmaceuticals, Inc. Method of treating corneal transplant rejection by using vegf antagonists
US7186699B2 (en) * 2003-06-03 2007-03-06 Cell Genesys, Inc. Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes
US7354578B2 (en) * 2003-06-06 2008-04-08 Regeneron Pharmaceuticals, Inc. Method of tumor regression with VEGF inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000075319A1 (en) * 1999-06-08 2000-12-14 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN5007014594, ＧＬＡＤＥ−ＢＥＮＤＥＲ ＪＵＬＩＡ， ｅｔ ａｌ．, ＥＸＰＥＲＴ ＯＰＩＮＩＯＮ ＯＮ ＢＩＯＬＯＧＩＣＡＬ ＴＨＥＲＡＰＹ．, 200304, Ｖｏｌ．３ Ｎｏ．２, ｐｐ．２６３−２７６ *
JPN5007014595, ＨＯＬＡＳＨ Ｊ． ｅｔ ａｌ, ＰＮＡＳ, 20020820, Ｖｏｌ．９９ Ｎｏ．１７, ｐｐ．１１３９３−１１３９８, US, ＮＡＴＩＯＮＡＬ ＡＣＡＤＥＭＹ ＯＦ ＳＣＩＥＮＣＥ *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013538337A (ja) * 2010-07-19 2013-10-10 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 膵臓癌の治療のためのベバシズマブ組合せ療法のための血漿バイオマーカー
US9657084B2 (en) 2014-01-25 2017-05-23 Chengdu Kanghong Biotechnologies Co., Ltd. Fusion protein inhibiting angiogenesis or growth and use thereof
KR101789501B1 (ko) * 2014-01-25 2017-10-26 쳉두 캉홍 바이오테크놀로지스 코. 리미티드 혈관의 신생 또는 성장을 억제하는 융합 단백질 및 그 용도

Also Published As

Publication number Publication date
JP2012067116A (ja) 2012-04-05
IL179515A0 (en) 2007-05-15
US20050276808A1 (en) 2005-12-15
US20080214466A1 (en) 2008-09-04
CN101102786A (zh) 2008-01-09
US20080188420A1 (en) 2008-08-07
US20080188419A1 (en) 2008-08-07
MXPA06014421A (es) 2007-05-04
US7479275B2 (en) 2009-01-20
US20080171703A1 (en) 2008-07-17
US20080214465A1 (en) 2008-09-04
WO2005123104A2 (en) 2005-12-29
US20080188418A1 (en) 2008-08-07
US7479272B2 (en) 2009-01-20
US7354580B2 (en) 2008-04-08
US7479273B2 (en) 2009-01-20
US7482001B2 (en) 2009-01-27
US7479274B2 (en) 2009-01-20
EP2583685A1 (en) 2013-04-24
WO2005123104A3 (en) 2006-04-27
AU2005254058A1 (en) 2005-12-29
US7482002B2 (en) 2009-01-27
EP1753442A2 (en) 2007-02-21
CA2567686A1 (en) 2005-12-29

Similar Documents

Publication Publication Date Title
JP2008502738A (ja) ヒトの癌を処置するための、ｖｅｇｆインヒビターの使用
RU2571220C2 (ru) Способ лечения рака антагонистом dll4 и химиотерапевтическим средством
TWI612971B (zh) 用於乳癌治療之抗-血管新生療法
KR20160048095A (ko) 교모세포종을 치료하기 위한 병용 요법
JP6563197B2 (ja) 卵巣癌の治療のための併用療法
JP2008535798A (ja) Ｖｅｇｆの阻害による貧血の処置
RU2740311C2 (ru) НАЦЕЛЕННЫЕ НА uPARAP КОНЪЮГАТЫ АНТИТЕЛО-ЛЕКАРСТВЕННОЕ СРЕДСТВО
JP2019032306A (ja) Ｄｌｌ４アンタゴニストによる処置の方法およびモニタリング
US20230227823A1 (en) Fmrp and cancer treatment
US7354582B2 (en) Use of VEGF antagonists for the treatment of malignant gliomas
CN102573909A (zh) 抗血管发生疗法用于治疗先前治疗过的乳腺癌
CN119255817A (zh) 包含抗ctla4和抗pd1的混合抗体的药物组合物及其治疗用途
WO2025250689A1 (en) Combination therapy with angiogenesis protein and immune checkpoint inhibitor with/without chemotherapeutics
HK1169328B (en) Method of treating cancer with dll4 antagonist and chemotherapeutic agent

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080124

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101124

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110121

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110519

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110711

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111110

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20111212